Skip to content

The Dallas Hereditary Spherocytosis Cohort Study

The Dallas Hereditary Spherocytosis Cohort Study

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01141621
Enrollment
55
Registered
2010-06-10
Start date
2010-05-31
Completion date
2013-05-31
Last updated
2013-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Spherocytosis

Keywords

HS, congenital hemolytic anemia, splenectomy, quality of life

Brief summary

The purpose of this study is to 1. better characterize the short term and long term natural history of hereditary spherocytosis (HS) including diagnosis, complications, and indications for and response to splenectomy 2. evaluate and describe the health-related quality of life in children with HS.

Detailed description

Patients with a new or established diagnosis of HS seen at Children's Medical Center will be asked to enroll in the study. Previous and current medical records will be reviewed to systematically catalogue their history of HS, including diagnosis, complications, hospitalizations, medications and laboratory data. Health-related quality of life questionnaires will be given to the patients and their parents at enrollment and periodically during the follow-up. Those who agree will have up to three small samples of blood collected and frozen for future laboratory studies of complications associated with HS and/or splenectomy. We anticipate enrolling approximately 200 children and young adults with HS in this study and following them until adulthood (age 18-21 years).

Interventions

None listed

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of HS with or without prior splenectomy * Age 0 - 21 years * Spanish-speaking subjects are eligible to participate

Exclusion criteria

* Unable to provide contact information for follow-up

Design outcomes

Primary

MeasureTime frameDescription
Health related quality of lifeApproximately at 5 yearsPedsQL measurement

Secondary

MeasureTime frameDescription
Primary indications for splenectomyApproximately at 5 yearsPrimary indication for splenectomy determined at time of splenectomy, if performed.
Complications of HSApproximately at 5 years and at 10 years
Complications of splenectomyApproximately at 5 years
Diagnosis of HSAt enrollment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026